Armistice Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Armistice Capital’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-40,400,067	Closed	-$9.97M	–	411
2026 Q1	$9.97M	Buy	+40,400,067	New	+$16.1M	0.18%	91
2024 Q3	–	Sell	-14,060,000	Closed	-$5.04M	–	312
2024 Q2	$5.04M	Sell	14,060,000 -2,898,477	-17%	-$1.57M	0.06%	116
2024 Q1	$11.4M	Buy	+16,958,477	New	+$12.3M	0.15%	93

Other funds holding SGMO

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

AIM

Axiom Investment Management New York $150M AUM

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

HIG

Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Armistice Capital's SGMO Position: Q2 2026 in Review

Armistice Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 40,400,067 shares — an estimated $9.97M sold.

Armistice Capital first reported a position in SGMO in Q1 2024 and held it in 3 quarters. The position peaked at $11.4M in Q1 2024. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

Armistice Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
Armistice Capital sold 40,400,067 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $9.97M.
Armistice Capital first reported a position in SANGAMO THERAPEUTICS INC in Q1 2024 and held it in 3 quarters.
Armistice Capital's SANGAMO THERAPEUTICS INC position peaked at $11.4M in Q1 2024.
6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.